PHARMACOKINETIC EVALUATION OF CISPLATIN IN CHILDREN WITH MALIGNANT SOLID TUMORS - A PHASE-II STUDY

  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (11-1) , 1021-1026
Abstract
In a phase II trial, cisplatin was given by 2 randomly assigned dose schedules to 53 children with malignant solid tumors. Both schedules, 30 mg/m2 per wk and 90 mg/m2 every 3 wk, were associated with drug-related toxic effects involving the renal, hematopoietic and neuromuscular systems. Pharmacokinetic studies indicated that the initial serum half-life of total Pt was 27.6 min with a terminal half-life of 44.4 h. Significant antitumor effect was noted in patients with neuroblastoma and malignant germ cell tumors. Use of cisplatin in combination therapy for patients with these diseases is indicated.